Sundial Growers General and Administrative Expenses 2011-2026 | SNDL

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Sundial Growers

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	38.4 M	40.6 M	84 M	7.72 M	1.42 M	-	-	-	-	-	-

All numbers in CAD currency

Indicator range from annual reports

Maximum	Minimum	Average
84 M	1.42 M	34.4 M

General and Administrative Expenses of other stocks in the Drug manufacturers industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Endo International plc ENDP	568 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	15.1 M	-	-	$ 36.6 M	USA
Cumberland Pharmaceuticals CPIX	11.9 M	$ 5.6	-1.23 %	$ 83.2 M	USA
HEXO Corp. HEXO	32.9 M	-	2.45 %	$ 38.1 M	Canada
Calliditas Therapeutics AB (publ) CALT	390 M	-	-0.1 %	$ 2.03 B	Schweden
AcelRx Pharmaceuticals ACRX	7.48 M	-	7.5 %	$ 6.35 M	USA
DURECT Corporation DRRX	10.5 M	-	-	$ 50.1 M	USA
Adamis Pharmaceuticals Corporation ADMP	13.2 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	138 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	10.5 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	18.5 M	-	-	$ 142 M	USA
Cronos Group CRON	42 M	$ 2.68	-2.55 %	$ 1.03 B	Canada
Athenex ATNX	44.9 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	153 M	$ 37.64	-0.03 %	$ 1.38 B	USA
Avadel Pharmaceuticals plc AVDL	181 M	-	-	$ 2.06 B	France
Catalent CTLT	935 M	-	-	$ 11.5 B	USA
Eagle Pharmaceuticals EGRX	107 M	-	-39.89 %	$ 27.7 M	USA
Canopy Growth Corporation CGC	170 M	$ 1.0	-0.99 %	$ 108 M	Canada
Organogenesis Holdings ORGO	326 M	$ 2.34	-1.68 %	$ 297 M	USA
Pacira BioSciences PCRX	294 M	$ 22.99	-1.58 %	$ 1.06 B	USA
Sonoma Pharmaceuticals SNOA	7.36 M	$ 1.09	-0.91 %	$ 1.35 M	USA
Aurora Cannabis ACB	97.3 M	$ 3.04	-1.3 %	$ 167 M	Canada
Solid Biosciences SLDB	38.9 M	$ 7.14	-1.11 %	$ 625 M	USA
Jupiter Wellness JUPW	35.7 M	-	-	$ 33.6 M	USA
Lannett Company LCI	81 M	-	1.15 %	$ 7.11 M	USA
OrganiGram Holdings OGI	19.1 M	$ 1.06	-1.85 %	$ 101 M	Canada
Tilray TLRY	165 M	$ 4.98	-2.73 %	$ 3.08 B	Canada
Evolus EOLS	221 M	$ 6.73	3.38 %	$ 434 M	USA
Emergent BioSolutions EBS	186 M	$ 8.32	-0.83 %	$ 445 M	USA
Veru VERU	19.9 M	$ 3.0	-7.98 %	$ 43.9 M	USA
Neoleukin Therapeutics NLTX	28.3 M	-	-	$ 193 M	Canada
Assertio Holdings ASRT	69 M	$ 23.48	0.04 %	$ 150 M	USA
ProPhase Labs PRPH	19.3 M	-	-	$ 5.07 M	USA
Radius Health RDUS	131 M	-	-	$ 1.42 B	USA
Bausch Health Companies BHC	3.44 B	$ 5.06	-1.94 %	$ 1.88 B	Canada
PetIQ PETQ	196 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	32.2 M	$ 6.65	1.99 %	$ 263 M	USA
Recro Pharma REPH	21 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	83.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	14.4 M	$ 4.23	-0.35 %	$ 211 M	USA
PLx Pharma PLXP	40 M	-	-27.8 %	$ 2.56 M	USA
Viatris VTRS	3.79 B	$ 16.48	1.04 %	$ 19.2 B	USA
Zomedica Corp. ZOM	24.5 M	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	14.2 M	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	14 M	$ 0.62	0.35 %	$ 22.3 M	USA
Tricida TCDA	37.6 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	2.45 M	$ 0.71	-6.82 %	$ 3.05 M	China
TherapeuticsMD TXMD	6.85 M	$ 2.2	20.88 %	$ 25.5 M	USA